An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus

Nephrogenic diabetes insipidus (NDI) patients produce large amounts of dilute urine. NDI can be congenital, resulting from mutations in the type-2 vasopressin receptor (V2R), or acquired, resulting from medications such as lithium. There are no effective treatment options for NDI. Activation of PKA...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JCI Insight
Prif Awduron: Klein, Janet D., Khanna, Ish, Pillarisetti, Ram, Hagan, Rachael A., LaRocque, Lauren M., Rodriguez, Eva L., Sands, Jeff M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2021
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8119225/
https://ncbi.nlm.nih.gov/pubmed/33724959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.146419
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg